Picture [LSUS] – The Business Web Portal 650x65px
Document › Details

InfanDx AG. (3/1/17). "Press Release: InfanDx AG Wins New Investor and Prepares for Round B Financing". Cologne & Bonn.

Organisations Organisation InfanDx AG
  Organisation 2 Arnika Beteiligungen GmbH (family office)
Products Product diagnostic test
  Product 2 venture capital
Index term Index term InfanDx–Arnika Beteiligungen: investment, 201703 investment by new investor Arnika Beteiligungen GmbH
Persons Person Meyer, Ron (InfanDx 201703 CEO)
  Person 2 Schwandner, Wolfgang (Arnika Beteiligungen 201703 Managing Director)

InfanDx welcomes its new investor Arnika Beteiligungen GmbH (Poing, near Munich) and thus enjoys significant tailwind in its approach to its next financing round coming at the second half of 2017. A “sizeable 6-digit sum” will help to more comfortably prepare and structure the projected development.

“We deeply appreciate the high level of trust while this advance investment helps to position ourselves optimally for the financing round in autumn 2017” states Ron Meyer, InfanDx’ CEO. Particularly the fact that both anchor investors of InfanDx, the Arnika Beteiligungen GmbH and the LSI Pre-SeedFonds GmbH declared readiness to co-invest in the upcoming round is seen as a strong signal to the investment community. „The strong combination of clear product focus with measurable benefit to healthcare and the high ethical impact for our youngest patients is exceptionally intriguing for us” explains Arnika CEO, Dr. Wolfgang Schwandner.

InfanDx currently benefits from an incubation program at Life Science Inkubator, Bonn (LSI) with support of the state North Rhine-Westphalia. This R&D phase is financed with more than 2 Mio. € and enables the project InfanDx to conduct two clinical research studies and significantly propel its development of a miniaturized test system.

This test, as first of its kind, will allow the early and reliable diagnosis of oxygen deficit during birth (perinatal asphyxia) and subsequent brain damage. It will fill a critical gap to enable the existing therapeutic approaches to reach early enough and help many affected children who are today overlooked and doomed to life long disability. Worldwide and each year >1 mio. babies suffer from NE, which makes it within the delivery period the largest single cause for life long morbidity. The biomarkers developed by the InfanDx-project will be the first diagnostic tool to reliably identify the babies in need early enough within the therapeutic time-window.

InfanDx AG develops products based on biomarkers derived from metabolomics research. Lead product is a diagnostic test on perinatal asphyxia (oxygen deficit during birth) and thereof resulting brain damage. Furthermore, InfanDx holds patent applications for intended following products.

Arnika Beteiligungen GmbH is a Family Office focusing on healthcare and life sciences .

Life Science Inkubator (LSI) offers room for visionary founders and entrepreneurs. Research projects from the fields of Biotech, Pharma and MedTech are taken into incubation for a maximum of three years to take critical steps towards marketability. As public-private partnership LSI enjoys coverage through federal German and NRW state government, private investors and leading research societies such as Max-Planck-, Fraunhofer- and Helmholtz-Society. This makes LSI a highly capable and unique concept throughout Germany.

Questions pls. to/ Rückfragen bitte an:

InfanDx AG
Ron Meyer (CEO)
Balthasarstr. 18
50670 Köln
T: +49 (0) 221 30089783
Fax: +49 (0) 221 2851975

Record changed: 2018-01-28


Picture [LSUS] – The Business Web Portal 650x65px

More documents for InfanDx AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSA] – The Business Web Portal 650x89px

» top